Physician profile
Hanhsing Wu
NPI 1114034832
$368.33
in general payments reported to CMS, 2019-2025
12 companies · $279 in 2025
The $279 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.29 · 2021: $13.34 · 2022: $31.80 · 2024: $31.41 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $295 · Education: $16.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $294.90 |
| Education | $16.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $62.83 | 2025 | Keytruda, Keytruda Qlex |
| Pfizer INC. | $61.14 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $32.29 | 2025 | Opdivo |
| Eisai INC. | $31.41 | 2024 | |
| Genentech USA, INC. | $30.22 | 2025 | Gazyva |
| Abbvie INC. | $28.79 | 2025 | |
| Incyte Corporation | $26.81 | 2025 | Niktimvo, Jakafi |
| Array Biopharma INC | $24.61 | 2025 | Braftovi, Lorbrena |
| Glaxosmithkline, LLC. | $20.72 | 2025 | Blenrep |
| Daiichi Sankyo INC. | $19.37 | 2025 | Datroway |
| Genmab U.S., INC. | $17.85 | 2025 | Epkinly |
| Seagen INC. | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hanhsing Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.